Prospects for a prophylactic HPV vaccine

Rationale and future implications for cervical cancer screening

Mark E. Sherman, Mark H. Schiffman, Howard Strickler, Allan Hildesheim

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

Cytologic screening in combination with ablative therapy has helped reduce cervical cancer mortality in the developed world. Despite the success of this approach, cervical cancer remains a major cause of death, especially among women with limited access to health care. Recognition that human papillomaviruses (HPVs) are the main etiologic agent in cervical cancer suggests that a prophylactic vaccine could reduce the incidence of HPV infection and, therefore, achieve cancer control with reduced reliance on costly screening programs. In this review, the rationale for developing a prophylactic HPV vaccine and the potential impact that vaccination would have on cervical cancer screening are discussed.

Original languageEnglish (US)
Pages (from-to)5-9
Number of pages5
JournalDiagnostic Cytopathology
Volume18
Issue number1
DOIs
StatePublished - 1998
Externally publishedYes

Fingerprint

Papillomavirus Vaccines
Early Detection of Cancer
Uterine Cervical Neoplasms
Health Services Accessibility
Papillomavirus Infections
Cause of Death
Vaccination
Vaccines
Mortality
Incidence
Neoplasms
Therapeutics

Keywords

  • Cervix
  • Cytology
  • Papillomavirus
  • Vaccine
  • VLP

ASJC Scopus subject areas

  • Anatomy

Cite this

Prospects for a prophylactic HPV vaccine : Rationale and future implications for cervical cancer screening. / Sherman, Mark E.; Schiffman, Mark H.; Strickler, Howard; Hildesheim, Allan.

In: Diagnostic Cytopathology, Vol. 18, No. 1, 1998, p. 5-9.

Research output: Contribution to journalArticle

Sherman, Mark E. ; Schiffman, Mark H. ; Strickler, Howard ; Hildesheim, Allan. / Prospects for a prophylactic HPV vaccine : Rationale and future implications for cervical cancer screening. In: Diagnostic Cytopathology. 1998 ; Vol. 18, No. 1. pp. 5-9.
@article{f70ba06e842f432ebd624a6da421b812,
title = "Prospects for a prophylactic HPV vaccine: Rationale and future implications for cervical cancer screening",
abstract = "Cytologic screening in combination with ablative therapy has helped reduce cervical cancer mortality in the developed world. Despite the success of this approach, cervical cancer remains a major cause of death, especially among women with limited access to health care. Recognition that human papillomaviruses (HPVs) are the main etiologic agent in cervical cancer suggests that a prophylactic vaccine could reduce the incidence of HPV infection and, therefore, achieve cancer control with reduced reliance on costly screening programs. In this review, the rationale for developing a prophylactic HPV vaccine and the potential impact that vaccination would have on cervical cancer screening are discussed.",
keywords = "Cervix, Cytology, Papillomavirus, Vaccine, VLP",
author = "Sherman, {Mark E.} and Schiffman, {Mark H.} and Howard Strickler and Allan Hildesheim",
year = "1998",
doi = "10.1002/(SICI)1097-0339(199801)18:1<5::AID-DC2>3.0.CO;2-G",
language = "English (US)",
volume = "18",
pages = "5--9",
journal = "Diagnostic Cytopathology",
issn = "8755-1039",
publisher = "Wiley-Liss Inc.",
number = "1",

}

TY - JOUR

T1 - Prospects for a prophylactic HPV vaccine

T2 - Rationale and future implications for cervical cancer screening

AU - Sherman, Mark E.

AU - Schiffman, Mark H.

AU - Strickler, Howard

AU - Hildesheim, Allan

PY - 1998

Y1 - 1998

N2 - Cytologic screening in combination with ablative therapy has helped reduce cervical cancer mortality in the developed world. Despite the success of this approach, cervical cancer remains a major cause of death, especially among women with limited access to health care. Recognition that human papillomaviruses (HPVs) are the main etiologic agent in cervical cancer suggests that a prophylactic vaccine could reduce the incidence of HPV infection and, therefore, achieve cancer control with reduced reliance on costly screening programs. In this review, the rationale for developing a prophylactic HPV vaccine and the potential impact that vaccination would have on cervical cancer screening are discussed.

AB - Cytologic screening in combination with ablative therapy has helped reduce cervical cancer mortality in the developed world. Despite the success of this approach, cervical cancer remains a major cause of death, especially among women with limited access to health care. Recognition that human papillomaviruses (HPVs) are the main etiologic agent in cervical cancer suggests that a prophylactic vaccine could reduce the incidence of HPV infection and, therefore, achieve cancer control with reduced reliance on costly screening programs. In this review, the rationale for developing a prophylactic HPV vaccine and the potential impact that vaccination would have on cervical cancer screening are discussed.

KW - Cervix

KW - Cytology

KW - Papillomavirus

KW - Vaccine

KW - VLP

UR - http://www.scopus.com/inward/record.url?scp=0031965314&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031965314&partnerID=8YFLogxK

U2 - 10.1002/(SICI)1097-0339(199801)18:1<5::AID-DC2>3.0.CO;2-G

DO - 10.1002/(SICI)1097-0339(199801)18:1<5::AID-DC2>3.0.CO;2-G

M3 - Article

VL - 18

SP - 5

EP - 9

JO - Diagnostic Cytopathology

JF - Diagnostic Cytopathology

SN - 8755-1039

IS - 1

ER -